Effect Of Ursodeoxycholic Acid on indirect Hyperbilirubinemia in Neonates Treated with phototherapy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017071515511N2

Enrollment

220

Registered

2017-08-21

Start date

2017-02-18

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperbilirubinemia. defects of catalase and peroxidase

Interventions

Intervention 1: Case Group: 10 mg / kg / day, BD diluted with water for UDCA capsules. Intervention 2: Control Group: Only Phototherapy.

Treatment - Drugs

Case Group: 10 mg / kg / day, BD diluted with water for UDCA capsules

Control Group: Only Phototherapy

Eligibility

Sex/Gender

All

Age

No minimum to 1 Days

Inclusion criteria

Inclusion criteria: Admission criteria: Neonates with nonconjunctive Hyperbilirubinemia weighing 2500-4000 gr; Breastfeeding, 37-41w GA; Age greater than 24h; Tbili = 14-20; Dbili <2mg / dl Exit criteria: Inconsistency of ABO, RH, G6PD negative; Negative septicemia; Diseases leading to Hyperbilirubinemia: Carpenter Najjar, Gilbert, Hyperthyroid hypertrophic hypothyroidism, Preterm and diabetic mothers

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Rate Tbili. Timepoint: 0, 12, 24 and 48 hours. Method of measurement: Spectrophotometry.	—

Secondary

Measure	Time frame
Rate BG , RH , TSH. Timepoint: first day. Method of measurement: blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Rona Akefi

Arak University of Medical Sciences

rahenorayaneh@yahoo.com;Mojtaba53hashemi@yahoo.com+98 86 3465 5314

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 17, 2026